Central hypersomnias in children

Increased daytime sleepiness is an important symptom of disturbed night sleep, which should not be neglected. Hypersomnia reduces the quality of life, complicates socialization, can provoke insomnia, impulsive behaviour, and even depression or suicidal tendencies. The causes of increased daytime sleepiness may be non-compliance with sleep hygiene, nighttime sleep disorders (obstructive sleep apnea syndrome, etc.). If these conditions are excluded, you need to pay attention to rare forms of sleep pathology included in the group of central hypersomnia.

Aim of the review: to determine the prevalence, pathogenesis, clinic, diagnosis, and treatment of hypersomnia in children.

Among the central hypersomnia, narcolepsy is more common than the rest in the population. Idiopathic hypersomnia and Kleine-Levin syndrome are more rare forms of pathology. The pathogenesis of central hypersomnia has not yet been sufficiently studied, disorders of the immune system are of key importance, but there may be other causes. The leading clinical manifestation is daytime sleepiness, which worsens the child’s quality of life. In the diagnosis of hypersomnia, polysomnography and multiple sleep latency test (MTLS) are of key importance, in some cases other diagnostic methods (MRI) should be used. Pharmacotherapy relieves the condition in sick children, but does not completely eliminate the symptoms. New medicines are being developed. Treatment of hypertension should be comprehensive, not limited to drug therapy.

Contribution:
Kozhevnikova O.V., Lebedev V.V. — concept and design of the review;
Lebedev V.V., Gazaryan A.A. — collection and processing of material, writing the text;
Kozhevnikova O.V. — editing the text.
All co-authors — approval of the final version of the article, responsibility for the integrity of all parts of the article.

Acknowledgment. The study had no sponsorship.

Conflict of interest. The authors declare no conflict of interest.

Received: October 16, 2024
Accepted: December 06, 2024
Published: December 25, 2024

1. Maski K., Trotti L.M., Kotagal S., Auger R., Swick T.J., Rowley J.A., et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. J. Clin. Sleep Med. 2021; 17(9): 1895–945. https://doi.org/10.5664/jcsm.9326

2. Kelmanson I.A. Clinical somnology of childhood [Klinicheskaya somnologiya detskogo vozrasta: uchebnoe posobie]. St. Petersburg: SpetsLit; 2021. https://elibrary.ru/qniist (in Russian)

3. Kalinkin A.L. Prevalence of the excessive daytime sleepiness in Russian Federation. Nervnomyschechnye bolezni. 2018; 8(4): 43–8. https://doi.org/10.17650/2222-8721-2018-8-4-43-48 https://elibrary.ru/ytgejn (in Russian)

4. Longstreth W.T. Jr., Koepsell T.D., Ton T.G., Hendrickson A.F., van Belle G. The epidemiology of narcolepsy. Sleep. 2007; 30(1): 13–26. https://doi.org/10.1093/sleep/30.1.13

5. Acquavella J., Mehra R., Bron M., Suomi J.M., Hess G.P. Prevalence of narcolepsy and other sleep disorders and frequency of diagnostic tests from 2013–2016 in insured patients actively seeking care. J. Clin. Sleep Med. 2020; 16(8): 1255–63. https://doi.org/10.5664/jcsm.8482

6. Miglis M.G., Guilleminault C. Kleine-Levin syndrome. Curr. Neurol. Neurosci. Rep. 2016; 16(6): 60. https://doi.org/10.1007/s11910-016-0653-6

7. Halioua B., Taieb J., Seneschal J., Corgibet F., Misery L., Marquié A., et al. Prevalence of excessive daytime sleepiness among patients with atopic dermatitis. Skin Health Dis. 2023; 3(4): e227. https://doi.org/10.1002/ski2.227

8. Dubessy A.L., Tezenas du Montcel S., Viala F., Assouad R., Tiberge M., Papeix C., et al. Association of central hypersomnia and fatigue in patients with multiple sclerosis: a polysomnographic study. Neurology. 2021; 97(1): 23–33. https://doi.org/10.1212/WNL.0000000000012120

9. Nevárez N., de Lecea L. Recent advances in understanding the roles of hypocretin/orexin in arousal, affect, and motivation. F1000Res. 2018; 7: F1000 Faculty Rev-1421. https://doi.org/10.12688/f1000research.15097.1

10. Mahoney C.E., Cogswell A., Koralnik I.J., Scammell T.E. The neurobiological basis of narcolepsy. Nat. Rev. Neurosci. 2019; 20(2): 83–93. https://doi.org/10.1038/s41583-018-0097-x

11. Han F., Lin L., Schormair B., Pizza F., Plazzi G., Ollila H.M., et al. HLA DQB1*06:02 negative narcolepsy with hypocretin/orexin deficiency. Sleep. 2014; 37(10): 1601–8. https://doi.org/10.5665/sleep.4066

12. Oh J., Cho E., Um Y.H., Oh S.H., Hong S.C. Narcolepsy is associated with an increased risk of HLA-related autoimmune diseases: Evidence from a nationwide healthcare system data in South Korea. Sleep Med. 2023; 105: 37–42. https://doi.org/10.1016/j.sleep.2023.03.006

13. Martinez-Orozco F., Fernandez-Arquero M., Vicario J., Lillo-Triguero L., Ameyugo E., Peraita-Adrados R. Long-Term outcome of a series of patients with narcolepsy Type 1 and comorbidity with immunopathological and autoimmune diseases. J. Clin. Med. Res. 2022; 14(8): 309–14. https://doi.org/10.14740/jocmr4758

14. Gool J.K., Zhang Z., Fronczek R., Amesz P., Khatami R., Lammers G.J. Potential immunological triggers for narcolepsy and idiopathic hypersomnia: Real-world insights on infections and influenza vaccinations. Sleep Med. 2024; 116: 105–14. https://doi.org/10.1016/j.sleep.2024.02.033

15. Gool J.K., Schinkelshoek M.S., Fronczek R. What triggered narcolepsy: H1N1 vaccination, virus, or both? Important lessons learned from China. Sleep. 2023; 46(3): zsad005. https://doi.org/10.1093/sleep/zsad005

16. Rosch R., Farquhar M., Gringras P., Pal D.K. Narcolepsy following yellow fever vaccination: a case report. Front. Neurol. 2016; 7: 130. https://doi.org/10.3389/fneur.2016.00130

17. Mahamid A., Bornstein R.J., Amir H. Pfizer/BioNTech SARS-CoV-2 vaccine as a potential trigger for the development of narcolepsy: a case report. J. Clin. Sleep Med. 2022; 18(10): 2503–6. https://doi.org/10.5664/jcsm.10134

18. Roya Y., Farzaneh B., Mostafa A.D., Mahsa S., Babak Z. Narcolepsy following COVID-19: A case report and review of potential mechanisms. Clin. Case Rep. 2023; 11(6): e7370. https://doi.org/10.1002/ccr3.7370

19. Mignot E., Bogan R.K., Emsellem H., Foldvary-Schaefer N., Naylor M., Neuwirth R., et al. Safety and pharmacodynamics of a single infusion of danavorexton in adults with idiopathic hypersomnia. Sleep. 2023; 46(9): zsad049. https://doi.org/10.1093/sleep/zsad049

20. Zan W., Yu-Heng Z., Shan J., Wei-Min Q., Zhi-Li H., Chang-Rui C. Case report: dysfunction of the paraventricular hypothalamic nucleus area induces hypersomnia in patients. Front. Neurosci. 2022; 16: 830474. https://doi.org/10.3389/fnins.2022.830474

21. Madan R., Pitts J., Patterson M.C., Lloyd R., Keating G., Kotagal S. Secondary narcolepsy in children. J. Child Neurol. 2021; 36(2): 123–7. https://doi.org/10.1177/0883073820954617

22. Al Shareef S.M., Basit S., Li S., Pfister C., Pradervand S., Lecendreux M., et al. Kleine-Levin syndrome is associated with LMOD3 variants. J. Sleep Res. 2019; 28(3): e12718. https://doi.org/10.1111/jsr.12718

23. Wenz E., Tafti M., Bassetti C.L.A. LMOD3 gene variant in familial periodic hypersomnolence. Sleep Med. 2022; 91: 105–8. https://doi.org/10.1016/j.sleep.2022.02.019

24. Maycock T.J., Rossor T., Vanegas M., Gringras P., Jungbluth H. Child neurology: common occurrence of narcolepsy type 1 and myasthenia gravis. Neurology. 2024; 103(3): e209598. https://doi.org/10.1212/WNL.0000000000209598

25. Leu-Semenescu S., Maranci J.B., Lopez R., Drouot X., Dodet P., Gales A., et al. Comorbid parasomnias in narcolepsy and idiopathic hypersomnia: more REM than NREM parasomnias. J. Clin. Sleep Med. 2022; 18(5): 1355–64. https://doi.org/10.5664/jcsm.9862

26. Mohammadi S., Moosaie F., Saghazadeh A., Mahmoudi M., Rezaei N. Metabolic profile in patients with narcolepsy: a systematic review and meta-analysis. Sleep Med. 2021; 81: 268–84. https://doi.org/10.1016/j.sleep.2021.02.040

27. Honda M., Shigematsu Y., Shimada M., Honda Y., Tokunaga K., Miyagawa T. Low carnitine palmitoyltransferase 1 activity is a risk factor for narcolepsy type 1 and other hypersomnia. Sleep. 2022; 45(10): zsac160. https://doi.org/10.1093/sleep/zsac160

28. Wilson A., Dongarwar D., Carter K., Marroquin M., Salihu H. The association between narcolepsy during pregnancy and maternal-fetal risk factors/outcomes. Sleep Sci. 2022; 15(3): 297–304. https://doi.org/10.5935/1984-0063.20220054

29. Yang Y., Zhang J., Han F., Xiao F. Not Only excessive daytime sleepiness but also depression symptoms, chronological age and onset-age were associated with impulsivity in narcolepsy Type 1 patients. Nat. Sci. Sleep. 2022; 14: 1857–66. https://doi.org/10.2147/NSS.S377372

30. Seo J., Lee S., Lee J., Jeon S., Hwang Y., Kim J., et al. Effects of sleep and impulsivity on suicidality in shift and non-shift workers. J. Affect. Disord. 2023; 338: 554–60. https://doi.org/10.1016/j.jad.2023.06.066

31. Tonetti L., Andreose A., Bacaro V., Grimaldi M., Natale V., Crocetti E. Different effects of social jetlag and weekend catch-up sleep on well-being of adolescents according to the actual sleep duration. Int. J. Environ. Res. Public Health. 2022; 20(1): 574. https://doi.org/10.3390/ijerph20010574

32. Inocente С., Gustin M., Lavault S., Guignard-Perret A., Raoux A., Christol N., et al. Quality of life in children with narcolepsy. CNS Neurosci. Ther. 2014; 20(8): 763–71. https://doi.org/10.1111/cns.12291

33. Strauss M., Griffon L., Van Beers P., Elbaz M., Bouziotis J., Sauvet F., et al. Order matters: sleep spindles contribute to memory consolidation only when followed by rapid-eye-movement sleep. Sleep. 2022; 45(4): zsac022. https://doi.org/10.1093/sleep/zsac022

34. Ren J., Zhao X., Su C., Li X., Zhou J. ADHD in narcolepsy: A closer look at prevalence and ties. Neurosci. Biobehav. Rev. 2024; 156: 105471. https://doi.org/10.1016/j.neubiorev.2023.105471

35. Shen Z., Shuai Y., Mou S., Shen Y., Shen X., Yang S. Case report: Cases of narcolepsy misdiagnosed as other psychiatric disorders. Front. Psychiatry. 2022; 13: 942839. https://doi.org/10.3389/fpsyt.2022.942839

36. Šonka K., Feketeová E., Nevšímalová S., Horvat E.M., Příhodová I., Dostálová S., et al. Idiopathic hypersomnia years after the diagnosis. J. Sleep Res. 2024; 33(2): e14011. https://doi.org/10.1111/jsr.14011

37. Tamura N., Komada Y., Inoue Y., Tanaka H. Social jetlag among Japanese adolescents: Association with irritable mood, daytime sleepiness, fatigue, and poor academic performance. Chronobiol. Int. 2022; 39(3): 311–22. https://doi.org/10.1080/07420528.2021.1996388

38. Maski K.P., Amos L.B., Carter J.C., Koch E.E., Kazmi U., Rosen C.L. Recommended protocols for the multiple sleep latency test and maintenance of wakefulness test in children: guidance from the American Academy of Sleep Medicine. J. Clin. Sleep Med. 2024; 20(4): 631–41. https://doi.org/10.5664/jcsm.10974

39. Lopez R., Barateau L., Laura Rassu A., Evangelista E., Chenini S., Scholz S., et al. Rapid eye movement sleep duration during the multiple sleep latency test to diagnose hypocretin-deficient narcolepsy. Sleep. 2023; 46(1): zsac247. https://doi.org/10.1093/sleep/zsac247

40. Xiao L., Chen A., Parmar A., Frankel L., Toulany A., Murray B.J., et al. Narcolepsy treatment: voices of adolescents. Behav. Sleep Med. 2022; 20(2): 260–8. https://doi.org/10.1080/15402002.2021.1916496

41. Davidson R.D., Biddle K., Nassan M., Scammell T.E., Zhou E.S. The impact of narcolepsy on social relationships in young adults. J. Clin. Sleep Med. 2022; 18(12): 2751–61. https://doi.org/10.5664/jcsm.10212

42. Brunel L., Brossaud E., Lioret J., Jaffiol A., Vanderghote L., Cuisinier L., et al. Effectiveness of an intervention program on physical activity in children with narcolepsy type 1. Sleep Med. 2024; 116: 138–46. https://doi.org/10.1016/j.sleep.2024.03.002

43. Zhao M., Zhang B., Tang J., Zhang X. The impact of sleep pattern in school/work performance during the COVID-19 home quarantine in patients with narcolepsy. Front Neurol. 2022; 13: 849804. https://doi.org/10.3389/fneur.2022.849804

44. Lecendreux M., Plazzi G., Dauvilliers Y., Rosen C., Ruoff C., Black J., et al. Long-term safety and maintenance of efficacy of sodium oxybate in the treatment of narcolepsy with cataplexy in pediatric patients. J. Clin. Sleep Med. 2022; 18(9): 2217–27. https://doi.org/10.5664/jcsm.10090

45. Dauvilliers Y., Arnulf I., Foldvary-Schaefer N., Morse M., Šonka K., Thorpy M., et al. Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study. Lancet Neurol. 2022; 21(1): 53–65. https://doi.org/10.1016/S1474-4422(21)00368-9

46. Bogan R., Thorpy M.J., Winkelman J.W., Dubow J., Gudeman J., Seiden D. Randomized, crossover, open-label study of the relative bioavailability and safety of FT218, a once-nightly sodium oxybate formulation: Phase 1 study in healthy volunteers. Sleep Med. 2022; 100: 442–7. https://doi.org/10.1016/j.sleep.2022.09.011

47. Evans R., Kimura H., Alexander R., Davies C., Faessel H., Hartman D., et al. Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients. Proc. Natl Acad. Sci. USA. 2022; 119(35): e2207531119. https://doi.org/10.1073/pnas.2207531119

48. Dauvilliers Y., Lecendreux M., Lammers G.J., Franco P., Poluektov M., Caussé C., et al. Safety and efficacy of pitolisant in children aged 6 years or older with narcolepsy with or without cataplexy: a double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2023; 22(4): 303–11. https://doi.org/10.1016/S1474-4422(23)00036-4

49. Vinckenbosch F., Lammers G., Overeem S., Chen D., Wang G., Carter L., et al. Effects of solriamfetol on on-the-road driving in participants with narcolepsy: A randomised crossover trial. Hum. Psychopharmacol. 2022; 38(1): e2858. https://doi.org/10.1002/hup.2858

50. Imanishi A., Omori Y., Ishido H., Sagawa Y., Han G., Mishima K., et al. Aripiprazole as a new treatment for the prolonged nocturnal sleep of patient with idiopathic hypersomnia. Psychiatry Clin. Neurosci. 2021; 75(10): 320–2. https://doi.org/10.1111/pcn.13290